The ANDI-generated report provides crucial reference information on brain white matter to medical professionals. Credit: Marcin Janiec / Shutterstock.com.

Imeka has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Advanced Neuro Diagnostic Imaging (ANDI) quantitative imaging software.

The ANDI-generated report offers crucial reference information on brain white matter to medical professionals, including neurologists and radiologists.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This software enables the extraction of white matter bundles, which link specific regions of the brain and perform microstructure analysis along these connections.

Imeka co-founder and scientific advisor Maxime Descoteaux said: “Imeka has spent the past 12 years developing novel neuroimaging technologies that play an influential role in the search for and development of cures for brain diseases.”

Leveraging modelling, tractography and fibre bundling algorithms, the device processes diffusion-weighted images for mapping microstructural properties of the white matter.

See Also:

A DICOM-encapsulated PDF report will be generated by ANDI, focusing on bundles that exhibit a significant deviation from the normative range.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The report also provides a detailed analysis of the microstructural and macrostructural values of all bundles.

Imeka CEO Jean-René Bélanger said: “We are pleased to announce FDA 510(k) clearance of ANDI, our quantitative imaging software and make the technology available to healthcare providers across the US – which is going to have a major impact on brain disease management in the coming years.

“This also comes at a very crucial time with the announcement of the addition of two new CPT 3 codes by the AMA for quantitative brain MRI assessment, which we expect our clients to be able to get reimbursement from, starting in January 2024.”